j. res. pharm. Journal of Research in Pharmacy 2630-6344 Marmara University 10.12991/jrespharm.1643793 Pharmaceutical Chemistry Farmasotik Kimya Formulation and characterization of puerarin loaded nanoparticles encapsulated in PDLG employing solvent evaporation method Ahirrao Pallavi İD İD Department of Pharmaceutical Chemistry, Chandigarh College of Pharmacy N Deshmukh Kirti Department of Natural products, National Institute of Pharmaceutical Education and Research (NIPER), Sector-67, SAS Nagar (Mohali)-160062 Gupta Aakshi Department of Pharmaceutical Chemistry, Chandigarh College of Pharmacy M Jachak Sanjay Department of Natural products, National Institute of Pharmaceutical Education and Research (NIPER), Sector-67, SAS Nagar (Mohali)-160062 03 03 2025 29 1 295 309 02 12 2024 05 04 2024 Copyright © 2010, Journal of Research in Pharmacy 2010 Journal of Research in Pharmacy

Puerarin (PU) nanoparticles were prepared by solvent evaporation method (using PDLG polymer), followed by lyophilization, in order to improve water solubility, systemic adsorption, and dissolution rate. PU preformulation parameters were studied, and optimization study of PU nanoparticles (PU-NPs) was carried out by employing Box–Behnken design (BBD), a response surface methodology. Under optimal conditions PU nanoparticles (PU-NPs) with mean particle size (MPS) 120.6± 0.03 nm and particle size distribution (PDI) 0.22 were prepared. The entrapment efficiency, drug loading and drug content in the PU-NPs were found to be, 90.21%, 14.56% and 98% respectively. The zeta potential at 25℃ was found to be -16.3 mV. PU-NPs were characterized by SEM, FTIR, XRD, TEM, stability, in-vitro release study and cytotoxicity. These results demonstrated that PU-NPs are non-cytotoxic and of smaller particle size than PU. Complete characterization of PU-NPs has shed light on their exceptional characteristics, thus making them a significant asset for subsequent research endeavors.

 Puerarin PDLG Cytotoxicity Solvent evaporation method Puerarin nanoparticles Novel formulation [1] Ayurvedic Pharmacopoeia of India, Department of Health, Ministry of Health and Family Planning, Government of India,New Delhi, India, 1999,Part 1 and 2, pp. 1–190. [2] Cao S, Li X, Yin H, Wang J, Liu J. Dietary puerarin supplementation improves immune response and antioxidant capacity of sows. Antioxidants. 2024; 3: 290. https://doi.org/10.3390/antiox13030290 [3] Singh H, Kriplani P, Kamboj S, Guarve K. Puerarin: An anticancer and anti-inflammatory agent. Recent Pat Anticancer Drug Discov. 2024;19: 18-36. https://doi.org/10.2174/1574892818666230111152024 [4] Adedapo A, Fagbohun A, Dawurung C, Oyagbemi A, Omobowale O, Yakubu A. The aqueous tuber extract of Pueraria tuberosa (Willd.) DC caused cytotoxic effect on HT 29 cell lines with down regulation of nuclear factor kappa B (NF-κB). J Complement Integr Med. 2017; 16(4): 20160119. https://doi.org/10.1515/jcim-2016-0119 [5] Basavaraj P, Shivakumar B, Shivakumar H. Evaluation of anticonvulsant activity of alcoholic extract of tubers of Pueraria Tuberosa (Roxb). Adv Pharmacol Toxicol. 2011; 12(1): 1-9. [6] Oza M, Kulkarni A. Formononetin treatment in type 2 diabetic rats reduces insulin resistance and hyperglycemia. Front Pharmacol. 2018; 9: 739. https://doi.org/10.3389/fphar.2018.00739 [7] Gupta R, Sharma R, Sharma A, Choudhary R, Bhatnager A, Joshi Y. Antifertility effects of Pueraria tuberosa root extract in male rats. Pharmaceut Biol. 2005; 42 (8): 603-609. https://doi.org/10.1080/13880200490902491 [8] Pandey N, Yadav D, Pandey V, Tripathi B. Anti-inflammatory effect of Pueraria tuberosa extracts through improvement in activity of red blood cell anti-oxidant enzymes. AYU. 2013; 34 (3): 297-301. https://doi.org/10.4103/0974-8520.123131 [9] Ye Z, Wu H, Chen X, Xie R, Zhang D, Sun H, Wang F, Li Z, Xia Q, Chen L, Chen T. Puerarin inhibits inflammation and oxidative stress in female BALB/c mouse models of Graves’ disease. Transl Pediatr. 2024; 16 (1): 38. https://doi.org/10.21037%2Ftp-23-370 [10] Shukla R, Banerjee S, Tripathi B. Antioxidant and antiapoptotic effect of aqueous extract of Pueraria tuberosa (Roxb. Ex Willd.) DC. On streptozotocin-induced diabetic nephropathy in rats. BMC Complement Altern Med. 2018; 18 (1): 156. https://doi.org/10.1186/s12906-018-2221-x [11] Verma S, Jain V, Singh D. Effect of Pueraria tuberosa DC.(Indian Kudzu) on blood pressure, fibrinolysis and oxidative stress in patients with stage 1 hypertension. Pak J Biol Sci. 2012; 15 (15): 742-747. https://doi.org/10.3923/pjbs.2012.742.747 [12] Sumalatha G, Awen B, Chandu B, Mukkanti K. Anti ulcerogenic & ulcer healing studies of aqueous extract of Pueraria tuberosa leaves on rats. Int J Pharm Bio Sci. 2010; 1 (4): 657-661. [13] Patel V, Mistry M, Shinde K, Syed R, Singh V, Shin S. Therapeutic potential of quercetin as a cardiovascular agent. Eur J Med Chem. 2018; 155: 889-904. https://doi.org/10.1016/j.ejmech.2018.06.053 [14] Sun XY, Chen JP, Shang JJ, Liu HX, Li X, Lou Y, Zhou HW. Traditional Chinese medicine injections with activating blood circulation, equivalent effect of anticoagulation or antiplatelet, for acute myocardial infarction: A systematic review and meta-analysis of randomized clinical trials. Complementary Ther Med. 2024; 13: 103039. https://doi.org/10.1097%2FMD.0000000000029089 [15] Tanwar Y, Goyal S, Ramawat K. Hypolipidemic effects of tubers of Indian kudzu (Pueraria tuberosa). J Herbal Med Toxicol 2008; 2 (1): 21-25. [16] Xia D, Zhang P, Yan F, Wei-Fu Y, and Meng-Ting. Hepatoprotective activity of PU against carbon tetrachloride induced injuries in rats: A randomized controlled trial. Food Chem Toxicol. 2013; 59: 90-95. https://doi.org/10.1016/j.fct.2013.05.055 [17] Patel J, Doshi N, Bhalerao A, Bonagiri R. Immunomodulatory activity of ethanolic extract of Pueraria tuberosa DC. Int J Sci Eng Res. 2016; 7 (11): 708-713. [18] Shukla R, Banerjee S, Tripathi B. Pueraria tuberosa extract inhibits iNOS and IL-6 through suppression of PKC-α and NF-kB pathway in diabetes-induced nephropathy. J Pharm Pharmacol. 2018; 70 (8): 1102-1112. http://dx.doi.org/10.1111/jphp.12931 [19] Rao V, Pujar B, Nimbal S, ShantakumarmS, Satyanarayana S. Nootropic activity of tuber extract of Pueraria tuberosa (Roxb). Indian J Exp Bio. 2008; 46(8): 591-598. [20] Xing G, Dong M, Li X, Zou Y, Fan L, Wang X, Cai D, Li C, Zhou L, Liu J, Niu Y. Neuroprotective effects of puerarin against beta-amyloid-induced neurotoxicity in PC12 cells via a PI3K-dependent signaling pathway. Brain Res Bull. 2011;85(3-4):212-218. https://doi.org/10.1016/j.brainresbull.2011.03.024 [21] Kambhoja S, Murthy K. Wound healing and anti-inflammatory activity of Pueraria tuberosa (Roxb Ex wild) DC. Biomed. 2007; 2 (2): 229-232. [22] Maji K, Pandit S, Banerji P, Banerjee D. Pueraria tuberosa: A review on its phytochemical and therapeutic potential. Nat Prod Res. 2014; 28 (23): 2111-2127. https://doi.org/10.1080/14786419.2014.928291 [23] Quan D, Xu G, Wu X. Studies on preparation and absolute bioavailability of a self-emulsifying system containing PU. Chem Pharm Bull. 2007; 55 (5): 800-803. https://doi.org/10.1248/cpb.55.800 [24] Li H, Dong L, Liu Y, Wang G, Wang G, Qiao Y. Biopharmaceutics classification of PU and comparison of perfusion approaches in rats. Int J Pharm. 2014; 466 (1-2): 133-138. https://doi.org/10.1016/j.ijpharm.2014.03.014 [25] Wang Y, Ma Y, Du Y, Liu Z, Zhang D, Zhang Q. Formulation and pharmacokinetics evaluation of PU nanocrystals for intravenous delivery. J Nanosci Nanotechnol. 2012; 12 (8): 6176-6184. https://doi.org/10.1166/jnn.2012.6436 [26] Tu L, Yi Y, Wu W, Hu F, Hu K, Feng J. Effects of particle size on the pharmacokinetics of PU nanocrystals and microcrystals after oral administration to rat. Int J Pharm. 2013; 458 (1): 135-140. https://doi.org/10.1016/j.ijpharm.2013.10.001 [27] Zielińska A, Carreiró F, Oliveira M, Neves A, Pires B, Venkatesh N, Durazzo A, Lucarini M, Eder P, Silva M, Santini A, Souto B. Polymeric nanoparticles: Production, characterization, toxicology and ecotoxicology. Molecules. 2020; 25(16): 3731. https://doi.org/10.3390/molecules25163731 [28] Bohrey S, Chourasiya V, Pandey A. Polymeric nanoparticles containing diazepam: Preparation, optimization, characterization, in-vitro drug release and release kinetic study. Nano Converg. 2016; 3: 1–7. https://doi.org/10.1186/s40580-016-0061-2 [29] Liu X, Huang R, Wan J. Puerarin: A potential natural neuroprotective agent for neurological disorders. Biomed. 2023; 1 (162): 114581. https://doi.org/10.1016/j.biopha.2023.114581 [30] Agrawal V, Patel R, Patel M. Design, characterization, and evaluation of efinaconazole loaded poly (D, L-lactide co-glycolide) nano-capsules for targeted treatment of onychomycosis. J Drug Deliv Sci Technol. 2023; 80: 104157. https://doi.org/10.1016/j.jddst.2023.104157 [31] Rampado R, and Peer D. Design of experiments in the optimization of nanoparticle-based drug delivery systems. J Control Release. 2023; 358: 398-419. https://doi.org/10.1016/j.jconrel.2023.05.001 [32] Rashid A, Muneer S, Wang T, Alhamhoom Y, Rintoul L, Izake L, Islam N. PU dry powder inhaler formulations for pulmonary delivery: Development and characterization. Plos One 2021; 16 (4): 0249683. https://doi.org/10.1371/journal.pone.0249683 [33] Tao Q, Meng Q, Li H, Yu H, Liu F, Du D, Peng S. HP-β-CD-PLGA nanoparticles improve the penetration and bioavailability of puerarin and enhance the therapeutic effects on brain ischemia–reperfusion injury in rats. Naunyn-Schmiedeberg's Arch Pharmacol. 2013; 386: 61-70. https://doi.org/10.1007/s00210-012-0804-5 [34] Li L, Li Y, Miao C, Liu R. improved therapeutic effect of puerarin-encapsulated PEG-PLGA nanoparticle on an in vitro cerebral infarction model. Adv Polym Technol. 2020; 1-7. https://doi.org/10.1155/2020/7145738 [35] Chen T, Liu W, Xiong S, Li D, Fang S, Wu Z, Chen X. Nanoparticles mediating the sustained puerarin release facilitate improved brain delivery to treat Parkinson’s disease. ACS Appl Mater Interfaces. 2019; 11(48): 45276 45289. https://doi.org/10.1021/acsami.9b16047 [36] Zhang Y, Li Y, Zhao X, Zu Y, Wang W, Wu W, Li Z. Preparation, characterization and bioavailability of oral puerarin nanoparticles by emulsion solvent evaporation method. RSC Adv. 2016; 6(74): 69889-69901. http://dx.doi.org/10.1039/C6RA08413C [37] Bairwa K, Jachak S. Anti-inflammatory potential of a lipid-based formulation of a rotenoid-rich fraction prepared from Boerhavia diffusa. Pharm Bio. 2015; 53 (8): 1231-1238. https://doi.org/10.3109/13880209.2014.971382 [38] Peres C, Matos I, Conniot J, Sainz V, Zupančič E, Silva M, Graca L, Gaspar S, Preat V, Florindo F. Poly (lactic acid) based particulate systems are promising tools for immune modulation. Acta Biomater. 2017; 48: 41-57. https://doi.org/10.1016/j.actbio.2016.11.012 [39] Bharate S, Kumar V, Vishwakarma A. Determining Partition Coefficient (Log P), Distribution Coefficient (Log D) and Ionization Constant (pKa) in Early Drug Discovery. Comb Chem High T Scr. 2016; 19(6): 461–469. https://doi.org/10.2174/1386207319666160502123917 [40] Singh S, Sharda N, Mahajan L. Spectrophotometric determination of pKa of nimesulide. Int J Pharm. 1999; 176 (2): 261-264. https://doi.org/10.1016/S0378-5173(98)00304-4 [41] Xu N, He C. Separation and purification of PU with solvent extraction. Sep Purif Technol. 2007; 56 (3): 397-400. https://doi.org/10.1016/j.seppur.2007.06.003 [42] Han E, Priefer R. A systematic review of various pKa determination techniques. Int J Pharm. 2023; 635: 122783. https://doi.org/10.1016/j.ijpharm.2023.122783 [43] Kalam A, Khan A, Khan S, Almalik A, Alshamsan A. Optimizing indomethacin-loaded chitosan nanoparticle size, encapsulation, and release using Box–Behnken experimental design. Int J Bio Macromol. 2016; 87: 329-340. https://doi.org/10.1016/j.ijbiomac.2016.02.033 [44] Zhao L, Liu A, Sun M, Gu J, Wang H, Wang S, Zhang J, Guo C, Duan R, Zhai N. Enhancement of oral bioavailability of PU by polybutylcyanoacrylate nanoparticles. J Nanomater. 2011; 2011: 126562. https://doi.org/10.1155/2011/126562 [45] Zhang F, Liu G, Shen W, and Gurunathan S. Silver nanoparticles: Synthesis, characterization, properties, applications, and therapeutic approaches. Int J Mol Sci. 2016; 17(9): 1534. https://doi.org/10.3390/ijms17091534. [46] Sapsford E, Tyner M, Dair J, Deschamps R, Medintz L. Analyzing nanomaterial bioconjugates: A review of current and emerging purification and characterization techniques. Anal Chem. 2011; 83 (12): 4453-4488. https://doi.org/10.1021/ac200853a [47] Qiang S, Gu L, Kuang Y, Zhao M, You Y, Han Q. Changes in the content of PU-PLGA nanoparticles in mice under the influence of alcohol and analysis of their antialcoholism. J Appl Biomater Funct Mater. 2023; 21: 22808000221148100. https://doi.org/10.1177/22808000221148100 [48] Weng J, Tong Y, Chow F. In vitro release study of the polymeric drug nanoparticles: development and validation of a novel method. Pharmaceutics. 2020; 12(8): 732. https://doi.org/10.3390/pharmaceutics12080732 [49] Facchin BM, Dos Reis GO, Vieira GN, Mohr ETB, da Rosa JS, Kretzer IF, Demarchi IG, Dalmarco EM. Inflammatory biomarkers on an LPS-induced RAW 264.7 cell model: A systematic review and meta-analysis. Inflamm Res. 2022;71(7-8):741-758. https://doi.org/10.1007/s00011-022-01584-0 [50] Guo Z, Xu Y, Xu L, Wang S, Zhang M. In vivo and in vitro immunomodulatory and anti-inflammatory effects of total flavonoids of Astragalus. Afr https://doi.org/10.21010/ajtcam.v13i4.10 J Tradit Complement Altern Med. 2016; 13(4): 60–73.